Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Operating Leases

Microsoft Excel

Adjustments to Financial Statements for Operating Leases

Bristol-Myers Squibb Co., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Total Assets
Total assets (as reported) 90,038 92,603 95,159 96,820 109,314
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Total assets (adjusted) 90,038 92,603 95,159 96,820 109,314
Adjustment to Total Debt
Total debt (as reported) 45,111 49,649 39,772 39,320 44,553
Add: Operating lease liability (before adoption of FASB Topic 842)2
Add: Current operating lease liabilities 202 181 162 136 169
Add: Non-current operating lease liabilities 1,826 1,370 1,530 1,261 874
Total debt (adjusted) 47,139 51,200 41,464 40,717 45,596

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1, 2 Equal to total present value of future operating lease payments.


Bristol-Myers Squibb Co., Financial Data: Reported vs. Adjusted



Adjusted Financial Ratios for Operating Leases (Summary)

Bristol-Myers Squibb Co., adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Total Asset Turnover1
Reported total asset turnover 0.54 0.52 0.47 0.48 0.42
Adjusted total asset turnover 0.54 0.52 0.47 0.48 0.42
Debt to Equity2
Reported debt to equity 2.44 3.04 1.35 1.27 1.24
Adjusted debt to equity 2.55 3.13 1.41 1.31 1.27
Return on Assets3 (ROA)
Reported ROA 7.83% -9.66% 8.43% 6.53% 6.40%
Adjusted ROA 7.83% -9.66% 8.43% 6.53% 6.40%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

Financial ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted total asset turnover ratio improved from 2023 to 2024 and from 2024 to 2025.
Adjusted debt to equity A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. Bristol-Myers Squibb Co. adjusted debt to equity ratio deteriorated from 2023 to 2024 but then slightly improved from 2024 to 2025.
Adjusted ROA A profitability ratio calculated as net income divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted ROA deteriorated from 2023 to 2024 but then improved from 2024 to 2025 not reaching 2023 level.

Bristol-Myers Squibb Co., Financial Ratios: Reported vs. Adjusted



Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Revenues 48,194 48,300 45,006 46,159 46,385
Total assets 90,038 92,603 95,159 96,820 109,314
Activity Ratio
Total asset turnover1 0.54 0.52 0.47 0.48 0.42
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Revenues 48,194 48,300 45,006 46,159 46,385
Adjusted total assets 90,038 92,603 95,159 96,820 109,314
Activity Ratio
Adjusted total asset turnover2 0.54 0.52 0.47 0.48 0.42

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Revenues ÷ Total assets
= 48,194 ÷ 90,038 = 0.54

2 Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= 48,194 ÷ 90,038 = 0.54

Activity ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted total asset turnover ratio improved from 2023 to 2024 and from 2024 to 2025.


Adjusted Debt to Equity

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total debt 45,111 49,649 39,772 39,320 44,553
Total BMS shareholders’ equity 18,473 16,335 29,430 31,061 35,946
Solvency Ratio
Debt to equity1 2.44 3.04 1.35 1.27 1.24
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Adjusted total debt 47,139 51,200 41,464 40,717 45,596
Total BMS shareholders’ equity 18,473 16,335 29,430 31,061 35,946
Solvency Ratio
Adjusted debt to equity2 2.55 3.13 1.41 1.31 1.27

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Debt to equity = Total debt ÷ Total BMS shareholders’ equity
= 45,111 ÷ 18,473 = 2.44

2 Adjusted debt to equity = Adjusted total debt ÷ Total BMS shareholders’ equity
= 47,139 ÷ 18,473 = 2.55

Solvency ratio Description The company
Adjusted debt-to-equity A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity. Bristol-Myers Squibb Co. adjusted debt-to-equity ratio deteriorated from 2023 to 2024 but then slightly improved from 2024 to 2025.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS 7,054 (8,948) 8,025 6,327 6,994
Total assets 90,038 92,603 95,159 96,820 109,314
Profitability Ratio
ROA1 7.83% -9.66% 8.43% 6.53% 6.40%
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS 7,054 (8,948) 8,025 6,327 6,994
Adjusted total assets 90,038 92,603 95,159 96,820 109,314
Profitability Ratio
Adjusted ROA2 7.83% -9.66% 8.43% 6.53% 6.40%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net earnings (loss) attributable to BMS ÷ Total assets
= 100 × 7,054 ÷ 90,038 = 7.83%

2 Adjusted ROA = 100 × Net earnings (loss) attributable to BMS ÷ Adjusted total assets
= 100 × 7,054 ÷ 90,038 = 7.83%

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as net income divided by adjusted total assets. Bristol-Myers Squibb Co. adjusted ROA deteriorated from 2023 to 2024 but then improved from 2024 to 2025 not reaching 2023 level.